Su-Jie Zhu
Overview
Explore the profile of Su-Jie Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Wang Y, Wang Y, Li X, Deng Q, Gao F, et al.
Acta Pharm Sin B
. 2025 Mar;
15(1):409-423.
PMID: 40041920
Homo- or heterodimeric compounds that affect dimeric protein function through interaction between monomeric moieties and protein subunits can serve as valuable sources of potent and selective drug candidates. Here, we...
2.
Kong W, Zhu J, Bi S, Huang L, Wu P, Zhu S
Imeta
. 2024 Jun;
2(3):e126.
PMID: 38867930
We used an integrated ensemble learning method to build a stable prediction model for severity in COVID-19 patients, which was validated in multicenter cohorts.
3.
Wang A, Ma H, Yi Y, Zhu S, Yu Z, Zhu J, et al.
Eur J Pharmacol
. 2023 Dec;
960:176116.
PMID: 38059443
Cardiac fibrosis (CF) in response to persistent exogenous stimuli or myocardial injury results in cardiovascular diseases (CVDs). Protein tyrosine phosphatase 1B (PTP1B) can promote collagen deposition through regulating AMPK/TGF-β/Smads signaling...
4.
Li S, Zhang T, Zhu S, Lei C, Lai M, Peng L, et al.
ACS Med Chem Lett
. 2022 Feb;
13(2):196-202.
PMID: 35178175
A series of brigatinib derivatives were designed and synthesized as new potent and selective EGFR inhibitors. One of the most potent and selective compounds strongly suppressed the EGFR and EGFR...
5.
Lu Y, Fan Z, Zhu S, Huang X, Zhuang Z, Li Y, et al.
EMBO Mol Med
. 2021 Nov;
14(1):e14296.
PMID: 34845836
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly...
6.
Yan X, Ayaz P, Zhu S, Zhao P, Liang L, Zhang C, et al.
J Med Chem
. 2020 Jul;
63(15):8502-8511.
PMID: 32672461
AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear....
7.
Shen J, Zhang T, Zhu S, Sun M, Tong L, Lai M, et al.
J Med Chem
. 2019 Jul;
62(15):7302-7308.
PMID: 31298540
Tertiary EGFR mutation induced resistance against osimertinib () is an emerging "unmet clinical need" for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as...
8.
Lu X, Zhang T, Zhu S, Xun Q, Tong L, Hu X, et al.
ACS Med Chem Lett
. 2018 Nov;
9(11):1123-1127.
PMID: 30429956
EGFR mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clinical need" for nonsmall cell lung cancer patients. The pyrimidopyrimidinone derivative JND3229 was identified as a...
9.
Zhao P, Yao M, Zhu S, Chen J, Yun C
Biochem Biophys Res Commun
. 2018 May;
502(3):332-337.
PMID: 29802850
Lung cancer is the leading cause of cancer deaths. Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype...
10.
Zhu S, Zhao P, Yang J, Ma R, Yan X, Yang S, et al.
Oncotarget
. 2018 Mar;
9(17):13652-13665.
PMID: 29568384
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M...